Understand the source comparison
Difference Between KPV and LL-37 — Research Peptide Comparison
Research from institutions studying peptide immunomodulation has revealed a persistent misconception: KPV and LL-37 are frequently grouped together in immune system research, yet they operate through fundamentally distinct mechanisms that don't overlap. KPV is
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Research from institutions studying peptide immunomodulation has revealed a persistent misconception: KPV and LL-37 are frequently grouped together in immune system research, yet they operate through fundamentally distinct mechanisms that don't overlap. KPV is a three-amino-acid fragment (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH), functioning primarily as an anti-inflammatory signalling molecule. LL-37 is a 37-amino-acid antimicrobial peptide cleaved from the human cathelicidin protein hCAP-18, acting as a direct pathogen defense mechanism with secondary immune-modulating properties.
- We've supplied both KPV 5MG and LL 37 to researchers for years, and the selection error rate remains high—choosing one when the research question demands the other wastes time, funding, and sample integrity. The distinction matters at the procurement stage, not after reconstitution.
- What is the difference between KPV and LL-37?
- KPV is a tripeptide fragment (molecular weight 341 Da) that inhibits NF-κB translocation and suppresses inflammatory cytokine production—it doesn't kill pathogens. LL-37 is a 37-residue antimicrobial peptide (4.5 kDa) that disrupts microbial membranes and recruits immune cells. KPV modulates inflammation downstream; LL-37 acts upstream as a first-line antimicrobial barrier. They share immune system involvement but address separate phases of the immune response.
- KPV and LL-37 aren't interchangeable research tools—they're answering different biological questions. The rest of this article covers the structural distinctions that drive their divergent mechanisms, the specific pathways each peptide influences, which research models favour one over the other, and the reconstitution and storage differences that affect experimental reproducibility.